

Table 3: Adjusted Multinomial logistic regression

	Transient vs Uncolonized RRR (95% CI)	P value	Persistent vs Uncolonized RRR (95% CI)	P value	Persist vs Transient RRR (95% CI)	P value
Age	0.99 (0.97-1.01)	0.331	<b>0.98 (0.96-0.99)</b>	<b>0.007</b>	0.98 (0.96-1.01)	0.186
Male gender	0.74 (0.41-1.36)	0.335	0.89 (0.55-1.45)	0.641	1.20 (0.62-2.31)	0.593
Nonwhite race	1.65 (0.77-3.52)	0.199	1.59 (0.66-3.85)	0.304	0.97 (0.61-1.53)	0.881
Charlson	1.00 (0.94-1.07)	0.962	1.00 (0.92-1.09)	0.981	1.00 (0.90-1.11)	0.993
<b>PSMS score</b>	<b>1.09 (1.00-1.19)</b>	<b>0.048</b>	<b>1.13 (1.04-1.23)</b>	<b>0.003</b>	1.04 (0.94-1.14)	0.442
Open Wounds	1.54 (0.57-4.11)	0.392	2.77 (0.94-8.13)	0.064	1.80 (0.57-5.73)	0.318
<b>Duration of study follow-up, mean (SD)</b>	1.01 (1.00-1.01)	0.063	<b>1.02 (1.01-1.02)</b>	<b>&lt;0.001</b>	<b>1.01 (1.00-1.01)</b>	<b>0.003</b>
Antibiotics	1.21 (0.64-2.30)	0.559	0.78 (0.38-1.60)	0.505	0.65 (0.33-1.28)	0.210

lengths of NH stay (1.01; 95% CI, 1.00–1.01;  $P = .003$ ). **Conclusions:** R-GNB colonization in vulnerable NH patients is common (407 [45.5%] of 896 and often persistent (94 [55%] of 171 patients with sufficient follow-up to assess persistence). Patients with persistent R-GNB had lower functional status, longer LOS, and higher readmission rates than those without. R-GNB decolonization should be investigated as a strategy to potentially improve outcomes among NH patients.

**Funding:** None

**Disclosures:** None

*Antimicrobial Stewardship & Healthcare Epidemiology* 2022;2(Suppl. S1):s53–s54

doi:10.1017/ash.2022.158

#### Presentation Type:

Poster Presentation - Poster Presentation

**Subject Category:** MDR GNR

#### Inpatient point-prevalence screening of New Delhi Metallo- $\beta$ -lactamase (NDM)-producing Enterobacteriales and *Candida auris*

Christian Greco; Heather Smith; Candice Fearon; Jennifer Flaherty; Simona Kendrick; Kimberly Malcolm; Marcy McGinnis; Manisha Shah; Kadiatu Banjoko; Anjali Zedek; Justin Smyer; Shandra Day; Nora Colburn; Christina Liscynsky and Michael Haden

**Background:** Carbapenem-resistant Enterobacteriales (CRE) are an increasing threat to patient safety but only a small percentage of CRE identified are NDMs. Since 2018, clinical CRE isolates have been submitted to the Ohio Department of Health for sequencing and NDM cases have notably increased since that time. *Candida auris* is an emerging pathogen with similar risk factors for colonization as CRE. **Methods:** A point-prevalence study was initiated after an index patient was identified with NDM CRE infection or colonization during their inpatient admission. Two patient populations were included in the study: current patients on the same unit as the index patient and currently hospitalized patients who overlapped on any unit with the index patient for at least 72 hours. Patients had perirectal screening for CRE (via PCR) and axilla or groin screening for *C. auris* (via Xpert Carba-R Assay). Patients were excluded if they had been discharged, expired, or refused testing. **Results:** We completed 5 point-prevalence studies from March 21, 2021, to October 15, 2021. The index patients were admitted at different times and across 2 campuses including medical, cardiac, and surgical ICUs as well as medical-surgical and inpatient rehabilitation units. Moreover, 3 species of NDM were identified from urine and 2 species were identified from bronchoalveolar lavage: *Enterobacter hormaechei*, *Citrobacter freundii*, and *Enterobacter cloacae* complex. *C. freundii* and *E. cloacae* complex both had dual mechanisms of NDM and KPC. Although some of the index patients overlapped temporally within the health system, none overlapped in the same unit or building. None of the patients had recently received health care outside the United States, although 1 patient had emigrated from Togo >5 years prior and 4 had had prior local healthcare exposure within 12 months of admission. Also, 147 patients were identified for screening; 105 consented, 32 declined, and 10 were excluded due to being discharged, deceased, or unable to consent. Inpatient point-prevalence screening tests for all patients tested ( $n = 105$ ) were negative for NDM CRE and *C. auris*. **Conclusions:** Despite an increase of inpatients with NDM CRE, evidence of patient-to-patient transmission was not identified, likely resulting from adherence to standard precautions. The diversity of species and lack of international travel suggests that these patients likely acquired NDM

CRE from a local reservoir in the community or healthcare settings. Given the continued increase in NDM CRE without traditional risk factors, it is critical for hospitals and public health agencies to collaborate to identify these organisms and that they develop surveillance programs to clarify risk factors for colonization.

**Funding:** None

**Disclosures:** None

*Antimicrobial Stewardship & Healthcare Epidemiology* 2022;2(Suppl. S1):s54

doi:10.1017/ash.2022.159

#### Presentation Type:

Poster Presentation - Poster Presentation

**Subject Category:** Molecular Epidemiology

#### Whole-genome sequencing to assess clonality in a series of prosthetic joint *Staphylococcus epidermidis* isolates – WITHDRAWN

Samantha Simon; Mohamad Sater; Ian Herriott; Miriam Huntley and Brian Hollenbeck

**Background:** Prosthetic joint infections (PJIs) are costly and cause increased morbidity and mortality for patients. *Staphylococcus epidermidis* is a common cause of both early postoperative and late-presenting PJIs. Although *S. epidermidis* is a normal part of the human skin microflora, its ability to form biofilm on implanted medical devices make it an important causative pathogen of PJIs. We investigated genetic, epidemiologic, and environmental factors contributing to *S. epidermidis* PJIs by performing whole-genome sequencing and clinical epidemiologic investigation of isolates collected from infected patients between 2017 and 2020. **Methods:** Patients with *S. epidermidis* isolated from a prosthetic joint that was placed at our orthopedic specialty hospital were identified using the microbiology laboratory records and electronic medical records. Whole-genome sequencing and single-nucleotide polymorphism (SNP)-based clonality analyses were performed using the epiXact service at Day Zero Diagnostics. These analyses included species identification, in silico MLST typing, phylogenomic analysis, as well as genotypic assessment of the prevalence of specific antibiotic resistance genes, virulence genes, and other relevant genes. For clonal isolates, additional reviews of surgical history and clinical data were performed. **Results:** In total, 62 *S. epidermidis* joint isolates were identified from 46 patients. Among these isolates, 52 were of sufficient purity to be used for genomic analysis (Fig. 1). A number of genes appeared in every isolate including *sepA*, *smr*, *cap*, *sesB*, *sesG*, and *embp*. Also, 6 *S. epidermidis* samples had a discrepancy between phenotypic resistance to oxacillin and the presence of the *mecA* resistance gene. We also identified 6 distinct clusters of isolates, all of which had SNP distances <10 base pairs (Fig. 2). Each cluster consisted of 2–4 patients. Cluster isolates accounted for 29.8% of all *S. epidermidis* prosthetic joint isolates. Most clonal isolates occurred in patients who were heavily exposed to different healthcare settings. Further epidemiologic investigation showed that some of these clonal isolates had ties to aspirations or procedures, whereas no clear connection could be determined for others. **Conclusions:** *S. epidermidis* isolated from clinical prosthetic joint samples




Fig. 1.




Fig. 2.

contains a high degree of genetic resistance, including a mismatch between presence of *mecA* and phenotypic oxacillin resistance and genetic propensity for chlorhexidine resistance. Mupirocin resistance was not observed. Of all isolates, 29.8% belonged to multiple clusters, confirming hospital spread of this commensal organism in some cases.

**Funding:** None

**Disclosures:** None

*Antimicrobial Stewardship & Healthcare Epidemiology* 2022;2(Suppl. S1):s54–s55

doi:10.1017/ash.2022.160

**Presentation Type:**

Poster Presentation - Poster Presentation

**Subject Category:** MRSA/VRE

**Targeted *Staphylococcus aureus* decolonization in acute inpatient and intensive care settings of an academic medical center**

David DiTullio; Courtney Takats and Sarah Hochman

**Background:** *Staphylococcus aureus* is a common cause of healthcare associated infections and is associated with high mortality. *S. aureus* colonization of skin and mucosa contributes to its pathogenesis. Universal *S. aureus* decolonization reduces methicillin-resistant *S. aureus* (MRSA) and other bloodstream infections among ICU patients. However, universal decolonization in acute-care settings has not shown a similar benefit. We describe a targeted decolonization protocol implemented at a large academic hospital across acute-care and intensive care settings. We assessed the impact of decolonization on *S. aureus*-related infections. **Methods:** Adults admitted in 2018–2019 to the medicine, oncology, transplant, and ICU services were screened for *S. aureus* colonization using nasal swabs for MRSA/MSSA by culture. Those with *S. aureus* detected underwent decolonization with 5 days of chlorhexidine 2% baths and mupirocin intranasal ointment. Decolonization was considered complete if given for 5 days. The primary outcome was *S. aureus* invasive infection from hospital day 3 until discharge, defined by positive clinical cultures from sterile sites. Secondary outcomes included 30-day readmission and 30-day mortality. The control population was patients with negative MRSA/MSSA nasal screening in the same hospital units. **Results:** In total, 4,465 (23%) of 19,065 screening tests were positive for MSSA (75%) or MRSA (25%). The median age was 69 years (IQR, 56–80), and the median length of stay (LOS) was 6 days (IQR, 4–10). Among patients with LOS  $\geq$  3 days, 541 (16%) completed decolonization and 2,161 (64%) received no decolonization. The rate of complete decolonization increased to 35% among those with LOS  $\geq$  7 days. In total, 802 screened patients developed invasive *S. aureus* infections. Of 4,437 colonized patients, 536 (12%) had invasive infections, compared with 265 (2.1%) invasive infections in 12,917 noncolonized patients. Among patients with *S. aureus* colonization, 24% of decolonized patients developed invasive infection and 13% of patients who were not decolonized developed invasive infection. Rates of 30-day readmission and mortality were 28% and 10%, respectively, among fully decolonized patients, versus

20% and 6.6% among those receiving no decolonization. **Conclusions:** These data provide an assessment of the efficacy of a targeted screening and decolonization program. Although decolonization did not reduce rates of invasive infection or secondary outcomes, further analysis is needed. Patients with longer lengths of stay are more likely to receive full decolonization but are also at higher risk of invasive infection, which may contribute to our unexpected results.

**Funding:** None

**Disclosures:** None

*Antimicrobial Stewardship & Healthcare Epidemiology* 2022;2(Suppl. S1):s55

doi:10.1017/ash.2022.161

**Presentation Type:**

Poster Presentation - Poster Presentation

**Subject Category:** Other

**Stethoscope hygiene, workflow, and patient safety: The crux of health-care-associated infections**

William Peacock; Stuart Kipper and Sean-Xavier Neath

**Objective:** We evaluated the impressions and perceived workflow consequences following installation of a touch-free aseptic stethoscope barrier dispenser in the clinical environment. **Methods:** Beginning in 2020, we conducted a volunteer survey of aseptic stethoscope diaphragm barrier (AseptiScope, San Diego, CA) users in multiple departments at 7 US healthcare facilities. A 10-question survey was presented on an iPad near the aseptic barrier dispenser, which was usually located in the patient exam room, to be available immediately after the practitioner completed their examination, which included the use of the stethoscope barrier. This evaluation was considered a quality improvement project and was exempt from institutional review board approval. For this analysis, only 1 survey per practitioner was included. **Results:** Overall, 147 surveys were obtained from 7 institutions geographically distributed across the United States, immediately after placement of the DiskCover system in the patient care environment. Responses were generally positive and included ease of use (95.2% rated easy or very easy), comparison to a disposable stethoscope (97.9% as similar to, improved over, or significant improvement), workflow changes (53.7% improvement, 97.3% no impact, or improved), and perceived effect on patient safety (90.3% felt that patient safety was improved or significantly improved). **Conclusions:** The use of a touch-free aseptic stethoscope barrier system was reported to be easy to use, superior to a disposable stethoscope, and an improvement to practitioner workflow and perceived patient safety.

**Funding:** AseptiScope, Inc.

**Disclosures:** None

*Antimicrobial Stewardship & Healthcare Epidemiology* 2022;2(Suppl. S1):s55

doi:10.1017/ash.2022.162

Hands Free Stethoscope Aseptic Barrier Dispenser



Fig. 1.